Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:47:24.883Z.
Calculation as of: 2026-10-06T18:47:24.883Z.
Quote observation: 2026-10-06T18:45:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a49bf55b95e7accb53c24ef9933cb867312288378507dab28e57e4bc75072383
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$24.18M
EV/EBITDA Ratio
N/A
TTM Avg
11456.84x
3Y Avg
11456.84x
5Y Avg
11456.84x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InspireMD, Inc. (NSPR) | $26.19M | N/A | N/A | N/A | N/A |
| iTonic Holdings Ltd. (ITOC)vs › | $26.46M | N/A | N/A | N/A | N/A |
| Tevogen Bio Holdings Inc. (TVGN)vs › | $27.15M | N/A | N/A | N/A | N/A |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.28M | N/A | N/A | N/A | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.54M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $27.88M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.18M | N/A | 11456.84x | 11456.84x | 11456.84x |
| Kyntra Bio, Inc. (KYNB)vs › | $23.96M | N/A | 70.33x | 70.33x | 70.33x |
| OneMedNet Corporation (ONMD)vs › | $28.87M | N/A | N/A | N/A | N/A |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.15M | N/A | 0.53x | 0.52x | 0.52x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
